[Use of etretinate (RO-10-9359) in intermittent doses and follow-up for 1 year in patients with psoriasis. Final report].
p6e results of the treatment of 21 cases of psoriasis with etretinate are reported. The initial doses was 1 mg./Kg./daily for 8 weeks and, after control of the disease, minimal doses alternative with placebo administration. This method permits to obtain good results with minimal side effects.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*
D005050:Etretinate
Empleo del etretinato (RO-10-9359) a dosis intermitentes y seguimiento por un año en pacientes de psoriasis. Informe final.